Clinical Trials Logo

SARS-CoV-2 clinical trials

View clinical trials related to SARS-CoV-2.

Filter by:

NCT ID: NCT04480957 Completed - SARS-CoV-2 Clinical Trials

Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects

Start date: August 4, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Determine safety and tolerability and immungenicity of investigational vaccine ARCT-021 in healthy adult volunteers.

NCT ID: NCT04479293 Recruiting - COVID-19 Clinical Trials

Post COVID-19 Functional Status in Egypt

Start date: July 1, 2020
Phase:
Study type: Observational

Since the outbreak of coronavirus disease - COVID-19 pandemic, most attention has focused on mode of transmission, clinical picture of the disease, treatment and prevention. In the coming weeks and months emphasis will gradually involve the post- acute care of COVID-19 survivors. It is anticipated that COVID-19 may have major impact on physical, cognitive, mental, social health status even in patients with mild disease. Moreover, pulmonary, radiologic, laboratory, sleep issues remain to be addressed

NCT ID: NCT04478019 Completed - COVID-19 Clinical Trials

SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding

SHIELD
Start date: July 7, 2020
Phase: Early Phase 1
Study type: Interventional

Essential workers in positions with increased likelihood of exposure to SARS-CoC-2 will be most impacted by the proposed project. Evidence has shown that the SARS-CoV-2 novel coronavirus is easily transmissable through close contact between individuals, especially during aerosol-generating procedures such as intubation of patients. The intervention proposed in this study (nasal and oral decontamination with povidone-iodine and chlorhexidine, respectively) presents an opportunity for a safe, effective, and feasible treatment to decontaminate the primary entry points for SARS-CoV-2. As such, the intervention to be studied in this project may protect healthcare and other essential workers by preventing transmission of SARS-CoV-2 from patients to healthcare workers, as well as the general public to essential worker,. and thus reducing the incidence of COVID-19 in these workers.

NCT ID: NCT04476914 Completed - Depression Clinical Trials

Stress Related Disorders in Family Members of COVID-19 Patients Admitted to the ICU

Start date: June 29, 2020
Phase:
Study type: Observational

Coronavirus disease 2019 (COVID-19) is a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This syndrome has been associated with high mortality, estimated to be about 1.7% of all infected in the US, though in those who develop acute respiratory distress syndrome (ARDS) in the context of the infection, mortality rates appear to be much higher, perhaps up to 70%. To avoid transmission of the virus, patient isolation has become the standard of care, with many hospitals eliminating visitors of any type, and particularly eliminating visitation to patients infected with COVID-19. These necessary, but restrictive, measures add stress to the ICU and particularly to the family members who are not only left with fear, but also many unanswered questions. In contrast to the Society of Critical Care Guidelines (SCCM) which recommend family engagement in the ICU and recent data from this study team which suggests engaging families in end-of-life situations reduces symptoms of Post-Traumatic Stress Disorder (PTSD) in family members, family members are now unable to say good-bye and unable to provide support to their loved-one throughout the process of the patients' ICU stay. The study hypothesizes is that these restrictive visiting regulations will increase rates of Post-intensive care syndrome- family (PICS-F) which includes symptoms of PTSD, depression, and anxiety and aim to evaluate for factors that either exacerbate these symptoms or protect from them.

NCT ID: NCT04473365 Completed - COVID-19 Clinical Trials

Rapid Diagnostic Profiling of SARS-CoV-2 (COVID-19)

Profile-Cov
Start date: July 20, 2020
Phase:
Study type: Observational

The investigators will evaluate the profile of the immune response of Ethiopian population and examine its relationship with the noted low CD4+ T-cell count and underlying immune activation status among participants with COVID-19 and will compare results with those residing in Europe. In addition, this project will evaluate the performance of various rapid diagnostic tests (RDTs) for SARS-CoV-2, taking into account the above-determined immune system characteristics. We will also evaluate the effect of co-infection with parasites on COVID-19 severity

NCT ID: NCT04473261 Recruiting - Covid19 Clinical Trials

Efficacy of Iodine Complex Against COVID-19 Patients

I-COVID-PK
Start date: July 14, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to measure the effect of Iodine complex in treating the COVID-19 patients to clear viral load of SARS-CoV-2 along with reduction in severity of symptoms and length of hospitalization of patients with COVID-19.

NCT ID: NCT04473183 Withdrawn - Covid19 Clinical Trials

Epidemiologic Assessment of SARS-CoV-2 (COVID-19) Prevalence in Minnesota

Start date: July 21, 2020
Phase:
Study type: Observational

The purpose of this epidemiologic study is to estimate the prevalence and incidence of anti-SARS-CoV-2 antibodies in at-risk, exposed, affected populations. The study will also estimate the risk of SARS-CoV-2 exposure in target population.

NCT ID: NCT04472611 Completed - SARS-CoV-2 Clinical Trials

Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial

COLSTAT
Start date: October 30, 2020
Phase: Phase 3
Study type: Interventional

This is a pragmatic randomized open-label study of the safety and efficacy of the combination of colchicine and Rosuvastatin in addition to standard of care (SOC) compared to SOC alone in hospitalized patients with SARS-CoV-2

NCT ID: NCT04472494 Terminated - COVID-19 Clinical Trials

Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

Start date: October 14, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept administered to hospitalized COVID-19 participants with respiratory compromise.

NCT ID: NCT04472078 Completed - SARS-CoV-2 Clinical Trials

Seroprevalence of Coronavirus Disease 2019 (COVID-19) Antibodies in a Vulnerable Neighbourhood, Buenos Aries Argentina

Start date: June 10, 2020
Phase:
Study type: Observational [Patient Registry]

Background The study aimed to establish the seroprevalence of SARS-COV-2 in an Argentinian slum three months after the first case was reported. Methods Between June 10th and July 1st, a cross-sectional design was carried out on people over 14 years old, selected from a probabilistic sample of households. Finger prick puncture ELISA test